Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia

Amy Moskop*, Lauren Pommert, Christina Baggott, Snehit Prabhu, Holly L. Pacenta, Christine L. Phillips, Jenna Rossoff, Heather E. Stefanski, Julie An Talano, Steve P. Margossian, Michael R. Verneris, G. Doug Myers, Nicole A. Karras, Patrick A. Brown, Muna Qayed, Michelle L. Hermiston, Prakash Satwani, Christa Krupski, Amy K. Keating, Rachel WilcoxCara A. Rabik, Vanessa A. Fabrizio, Vasant Chinnabhandar, A. Yasemin Goksenin, Kevin J. Curran, Crystal L. Mackall, Theodore W. Laetsch, Erin M. Guest, Erin H. Breese, Liora M. Schultz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Infants with B-cell acute lymphoblastic leukemia (B-ALL) have poor outcomes because of chemotherapy resistance leading to high relapse rates. Tisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CART) therapy, is US Food and Drug Administration approved for relapsed or refractory B-ALL in patients #25 years; however, the safety and efficacy of this therapy in young patients is largely unknown because children,3 years of age were excluded from licensing studies. We retrospectively evaluated data from the Pediatric Real-World CAR Consortium to examine outcomes of patients with infant B-ALL who received tisagenlecleucel between 2017 and 2020 (n 5 14). Sixty-four percent of patients (n 5 9) achieved minimal residual disease-negative remission after CART and 50% of patients remain in remission at last follow-up. All patients with high disease burden at time of CART infusion (.M1 marrow) were refractory to this therapy (n 5 5). Overall, tisagenlecleucel was tolerable in this population, with only 3 patients experiencing $grade 3 cytokine release syndrome. No neurotoxicity was reported. This is the largest report of tisagenlecleucel use in infant B-ALL and shows that this therapy is safe and can be effective in this population. Incorporating this novel immunotherapy into the treatment of infant B-ALL offers a promising therapy for a highly aggressive leukemia.

Original languageEnglish (US)
Pages (from-to)4251-4255
Number of pages5
JournalBlood Advances
Issue number14
StatePublished - Jul 26 2022
Externally publishedYes

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this